Table 2.
Treatments evaluated for amyotrophic lateral sclerosis (ALS) that might be suitable for treatment of motor function deficits of WNV. Reviewed in (Morrison, 2002).
| Antiglutamate agents | Calcium regulators |
|---|---|
| Riluzole | Verapamil |
| L-threonine | Nimodepine |
| Dextromethorphan | |
| Lamotrigine | Cholinergic system |
| Gabapentin | Pysostigimine |
| 3-4 diaminopyridine | |
| Neurotrophic agents | Tetrahydroaminoacridine |
| CNTF | |
| BDNF | Antioxidants |
| GDNF | Topiramate |
| IGF-1 | D-penicillamine |
| TRH | Selegiline |
| Xaliproden | N-acetyl cysteine |
| Vitamin E | |
| Immunomodulators | |
| Azathioprine | Mitochondrial function |
| Cyclophosphamide | Creatine |
| Cyclosporine |